Review article: Nonalcoholic fatty liver disease and hepatitis C virus - Partners in crime

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 10, 2008, Pages 855-865

  Blonsky, J J ^a   Harrison, S A ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ANTIVIRUS AGENT; GLITAZONE DERIVATIVE; INTERFERON; METFORMIN; PEGINTERFERON; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RIBAVIRIN; ROSIGLITAZONE;

ANTIVIRAL THERAPY; CANCER RISK; DISEASE COURSE; FATTY LIVER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER FIBROSIS; MEDLINE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FATTY LIVER; HEPATITIS C; HUMANS; LIVER NEOPLASMS; OBESITY; TREATMENT OUTCOME;

EID: 42149193788     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03672.x     Document Type: Review

References (95)

1. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Am J Gastroenterol 2005 100 : 1091 8.
2. Bialek SR, Terrault NA. The changing epidemiology and natural history of hepatitis C virus infection. Clin Liv Dis 2006 10 : 697 715.
3. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1992 through 2002. Ann Intern Med 2006 144 : 705 14.
4. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980 55 : 434 8.
5. Browning JD, Szeczepaniack LS, Dobbins R, et al. Prevelance of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004 40 : 1387 95.
6. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study. Hepatology 2005 42 : 45 52.
7. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006 55 : 123 30.
8. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004 126 : 586 97.
9. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006 130 : 1636 42.
10. Ohata K, Hamasaki K, Toriyama K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003 97 : 3036 43.
11. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003 38 : 75 85.
12. Younossi ZM, McCullough AJ, Ong JP, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004 38 : 705 9.
13. Bedossa P, Moucari R, Chelbi E, et al. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology 2007 46 : 380 6.
14. Ong JP Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed non-alcoholic fatty liver disease. Liver 2001 21 : 266 71.
15. Brunt EM, Ramrakhiani S, Cordes BG, et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003 16 : 49 56.
16. Conjeevaram HS, Kleiner DE, Everhart JE, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007 45 : 80 7.
17. Hu KQ, Currie SL, Shen H, Cheung RC, et al. Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans. Dig Dis Sci 2007 52 : 570 8.
18. Tsochatzis E, Papatheodoridis GV, Manesis EK, et al. Hepatic Steatosis in Genotype 4 Chronic Hepatitis C is Mainly Because of Metabolic Factors. Am J Gastroenterol 2007 102 : 634 41.
19. Adinolfi LE, Durante-Mangoni E, Zampino R, Ruggiero G. Review article: hepatitis C virus-associated steatosis - pathogenic mechanisms and clinical implications. Aliment Pharmacol Ther 2005 22 (S2 52 5.
20. Verma S, Bonacini M, Govindarajan S, Kanel G, Lindsay KL, Redeker A. More advanced hepatic fibrosis in Hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis. Am J Gastroenterol 2006 101 : 1817 23.
21. Iacono OL, Venezia G, Petta S, et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007 25 : 1181 91.
22. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin in chronic liver diseases. Am J Gastroenterol 2006 101 : 2629 40.
23. Anty R, Gelsi E, Giudicelli J, et al. Glucose intolerance and hypoadiponectinemia are already present in lean patients with chronic hepatitis C infected with genotype non-3 viruses. Eur J Gastroenterol Hepatol 2007 19 : 671 7.
24. Durante-Mangoni E, Zampino R, Marrone A, Tripodi MF, et al. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther 2006 24 : 1349 57.
25. Jonsson JR, Moschen AR, Hickman IJ, Richardson MM, et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 2005 43 : 929 36.
26. Widjaja A, Wedemeyer H, Tillmann HL, et al. Hepatitis C and the leptin system: bound leptin levels are elevated in patients with hepatitis C and decrease during antiviral therapy. Scand J Gastroenterol 2001 36 : 426 31.
27. Romero-Gómez M, Castellano-Megias VM, Grande L, et al. Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol 2003 98 : 1135 41.
28. Manolakopoulos S, Bethanis S, Liapi C, et al. An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study. BMC Gastroenterol 2007 7 : 17.
29. Eguchi Y, Mizuta T, Yasutake T, et al. High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. World J Gastroenterol 2006 12 : 556 60.
30. Myers RP, Messous D, Poynard T, Imbert-Bismut F. Association between leptin, metabolic factors and liver histology in patients with chronic hepatitis C. Can J Gastroenterol 2007 21 : 289 94.
31. Cua IH, Hui JM, Bandara P, et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007 46 : 66 73.
32. Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A. Tumor necrosis factor-α-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol 2003 98 : 2751 6.
33. Valenti L, Pulixi E, Francanzani AL, et al. TNFα genotype affects TNFα release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. J Hepatol 2005 43 : 944 50.
34. Lecube A, Hernández C, Genescà J, Simó R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients. Diabetes Care 2006 29 : 1096 101.
35. Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklehaimanot S, Akhtar AJ. Hepatitis C, metabolic syndrome, and inflammatory markers: results from the third national health and nutrition examination survey[NHANES III]. Diabetes Res Clin Pract 2007 75 : 320 6.
36. Yazicioglu G, Isitan F, Altunbas H, et al. Insulin resistance in chronic hepatitis C. Int J Clin Pract 2004 58 : 1020 2.
37. Harrison SA. Correlation between insulin resistance and hepatitis C viral load. Hepatology 2006 43 : 1168 9.
38. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008 134 : 412 23.
39. Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000 133 : 592 9.
40. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003 38 : 50 6.
41. Hadziyannis S, Karamanos B. Diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999 29 : 605.
42. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000 75 : 355 9.
43. Bahtiyar G, Shin JJ, Aytaman A, Sowers JR, McFarlane SI. Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep 2004 4 : 194 8.
44. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999 29 : 328 33.
45. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004 126 : 840 8.
46. Moriya K, Yotsuyanagi H, Shintani Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997 78 : 1527 31.
47. Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007 102 : 570 6.
48. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006 55 : 529 35.
49. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003 38 : 1384 92.
50. Miyamoto H, Moriishi K, Moriya K, et al. Involvement of the PA28gamma-dependent pathway in insulin resistance induced by hepatitis C core protein. J Virol 2006 81 : 1727 35.
51. Moriishi K, Mochizuki R, Moriya K, et al. Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. PNAS 2007 104 : 1611 66.
52. Waris G, Felmlee DJ, Negro F, Siddiqui A. Hepatitis C Virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol 2007 81 : 8122 30.
53. Moriya K, Nakagawa K, Santa T, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001 61 : 4365 70.
54. Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002 122 : 366 75.
55. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001 33 : 1358 64.
56. Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J Viral Hepat 2006 13 : 73 80.
57. Matos C, Perez R, Pacheco M, et al. Steatosis in chronic hepatitis C: relationship to the virus and host risk factors. J Gastroenterol Hepatol 2006 21 : 1236 9.
58. Hourioux C, Patient R, Morin A, et al. The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut 2007 56 : 1302 8.
59. Jackel-Cram C, Babiuk L, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype 1-b core. J Hepatol 2006 46 : 999 1008.
60. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002 16 : 185 94.
61. Mirandola S, Realdon S, Iqbal J, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterol 2006 130 : 1661 9.
62. Solis-Herruzo J, Perez-Carreras M, Rivas E, et al. Factors associated with the presence of nonalcoholic steatohepatitis in patients with chronic hepatitis C. Am J Gastroenterol 2005 100 : 1091 8.
63. Bedossa P, Moucari R, Chelbi E, et al. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology 2007 46 : 380 7.
64. Castera L, Hezode C, Roudot-Thoraval F, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003 52 : 288 92.
65. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstål R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002 37 : 837 42.
66. Bugianesi E, Marchesini G, Gentilcore E, et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 2006 44 : 1648 55.
67. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003 125 : 1695 704.
68. Taura N, Ichikawa T, Hamasaki K, et al. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol 2006 101 : 2752 9.
69. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005 100 : 1509 15.
70. Gabriel A, Ziólkowski A, Radlowski P, Tomaszek K, Dziambor A. Hepatocyte steatosis in HCV patients promotes fibrosis by enhancing TGF-β liver expression. Hepatol Res 2008 38 : 141 6.
71. Piche T, Vandenbos F, Abakar-Mahamat A, et al. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepat 2004 11 : 91 6.
72. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998 4 : 1065 7.
73. Kumar D, Farrell GC, Kench J, George J. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepat 2005 20 : 1395 400.
74. Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 2007 109 : 2490 6.
75. Takuma Y, Nouso K, Makino Y, et al. Hepatic steatosis correlated with the postoperative recurrence of hepatitis C virus-associated hepatocellular carcinoma. Liver Int 2007 27 : 620 6.
76. Choi J, Ou JH. Mechanisms of liver injury: oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 2006 290 : 847 51.
77. Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic Hepatitis C. Hepatology 2006 43 : 1177 86.
78. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003 38 : 639 44.
79. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005 128 : 636 41.
80. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004 40 : 484 90.
81. Harrison SA, Brunt EM, Qazi RA, et al. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005 3 : 604 9.
82. Westin J, Lagging M, Dhillon AP, et al. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepatol 2007 14 : 29 35.
83. Bressler B, Wang K, Gries JM, et al. Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN Alpha2A(40 KD). Hepatology 2005 42 : 661A.
84. Fried M, Jensen D, Rodriguez-Torres M, et al. Improved sustained virological response (SVR) rates with higher, fixed doses of peginterferon alfa-2A (40 KD) plus ribavirin in patients with difficult to cure characteristics. Hepatology 2006 44 : 314A.
85. Zimmerer JM, Lesinski GB, Kondadasula SV, et al. IFN-alpha-induced signal transduction, gene expression and antitumor activity. J Immunol 2007 178 : 4832 45.
86. DiBona D, Cippitelli M, Fionda C, et al. Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway. J Hepatology 2006 45 : 271 9.
87. Hsu CS, Liu CJ, Liu CH, et al. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 2008 28 : 271 7.
88. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002 51 : 89 94.
89. Melhem A, Stern M, Shibolet O, et al. Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. J Clin Gastroenterol 2005 39 : 737 42.
90. Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of D-alpha-tocpherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997 113 : 1069 73.
91. Look MP, Gerard A, Rao GS, et al. Interferon/antioxidant combination therapy for chronic hepatitis C-a controlled pilot trial. Antiviral Res 1999 43 : 113 22.
92. Harrison SA. Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 2006 40 : 68 76.
93. Belfort R, Harrison SA, Brown K, et al. A placebo controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. NEJM 2006 355 : 2297 307.
94. Grande L, Madrazo A, Viloria MM, et al. Influence of insulin resistance and ribavirin dosage in viral dynamic of patients with chronic hepatitis C genotype 1 treated with peginterferon and ribavirin [abstract]. J Hepatol 2007 46 : S241.
95. Mizuta T, Eguchi Y, Kawaguchi Y, et al. Whole-body, not only liver, insulin sensitivity is strongly associated with an early and sustained virologic response to peginterferon plus ribavirin treatment in patients with chronic hepatitis C genotype 1b and high viral load [abstract]. Hepatology 2007 46 : 371A 2A.